Literatur
-
1
Bryan P Y.
Double jeopardy: balance between bleeding and stent thrombosis with prolonged dual antiplatelet therapy after drug-eluting stent implantation.
Cardiovasc Reva Med.
2006;
7
155-158
-
2
Merrit J C, Bhatt D L.
The efficacy and safety of perioperative antiplatelet therapy.
J Thromb Thrombolysis.
2002;
13
97-103
-
3
Lecompte T, Hardy J F.
Antiplatelet agents and perioperative bleeding.
Can J Anesth.
2006;
53
S103-S112
-
4
Anand S S, Yusuf S.
Oral anticoagulants in patients with coronary artery disease.
J Am Coll Cardiol.
2003;
41
(Suppl 4)
62S-69S
-
5
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H.
Warfarin, aspirin, or both after myocardial infarction.
N Engl J Med.
2002;
347
969-974
-
6
Lee S W, Chen M Z, Chan H W. et al .
No subacute thrombosis and femoral bleeding complications under full anticoagulation in 150 consecutive patients receiving non-heparin-coated intracoronary Palmaz-Schatz stents.
Am Heart J.
1996;
132
1135-1146
-
7
Leon M B, Baim D S, Popma J J. et al .
A clinical trial comparing three antithrombotic-drug regimes after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators.
N Engl J Med.
1998;
339
1665-1671
-
8
Templin C, Schaefer A, Stumme B. et al .
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Clin Res Cardiol.
2006;
95
122-126
-
9
Sauer H, Leschke M.
Empfehlungen zur peri-prozeduralen Thrombozytenfunktionshemmung.
Dtsch Med Wochenschrift.
2006;
131
400-402
-
10
Rosenfeldt M T. et al .
Diagnostische und therapeutische Eingriffe bei Patienten mit antithrombotischer Medikation: Was ist zu beachten?.
Dtsch Med Wochenschr.
2006;
131
982-986
Prof. Dr. med. Hanno Riess
für die Autoren: MT Rosenfeldt, W Haverkamp, R Trappe, P Kujath, H Riess
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie
Augustenburger Platz 1
13353 Berlin
Email: hanno.riess@charite.de
